SWOT Analysis: Cisplatin-Ineligibility Flag for Pre-Surgery Bladder Cancer Referral
An EHR-embedded triage tool that screens every new muscle-invasive bladder cancer diagnosis for cisplatin ineligibility (renal function, hearing, neuropathy, performance status) and automatically refers flagged patients to medical oncology before cystectomy is scheduled — capturing the neoadjuvant window where the new enfortumab vedotin + pembrolizumab benefit was demonstrated.
The framework reveals a high-impact clinical opportunity to close a critical gap in the standard of care for cisplatin-ineligible bladder cancer patients. While the clinical evidence for survival benefit is strong, the primary risks are operational friction within EHR workflows and the potential for trial-to-practice generalizability gaps.
Strengths4
Weaknesses3
Opportunities3
Threats3
Essential for evaluating the internal strength of the clinical evidence against the external threat of physician inertia or workflow resistance. · Generated 2026-10-18 by cavi/gemma4-31b-it-awq-4bit-32kAI-generated